Compelo Packaging - Latest industry news and analysis is using cookies

ContinueLearn More
Close
Dismiss

Pfizer recalls cough syrup medicine over labeling error

Pharmaceutical company in the US Pfizer has announced the recall of its cough syrup medicine over a labeling issue, the Food and Drug Administration (FDA) announced.

The recalled product includes Robitussin DM product, which contains Dextromethorphan HBr 15 mg and Guaifenessin 100 mg per 5mL.

According to FDA, the products have discrepancies on both the primary label and carton regarding dosage instructions for children two to six years old, and the wrong label states that dosage for the said age group is 2.5mL or equivalent to one teaspoonful, when the correct dosage should be only half a teaspoon.

The continuous distribution of the recalled product is expected to present health risk to the consuming sector of the public and the consumers who may have purchased them are advised to discontinue using them and coordinate with Pfizer immediately.